Pfizer new drug could provide a new treatment option for postmenopausal women

Pfizer new drug BZA/CE could provide a new treatment option for symptomatic postmenopausal women with a uterus – Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September_21-24 in Washington, D.C.

Soy isoflavone tablets not reducing bone loss or menopausal symptoms

Soy tablets not associated with reduction in bone loss or menopausal symptoms in women – Soy isoflavone tablets do not appear to reduce bone loss or menopausal symptoms in women within the first five years of menopause, revealed by researchers recently in a study reported in Archives of Internal Medicine.

Zytiga approved for late stage prostate cancer

U.S. Food and Drug Administration (FDA) approves Zytiga for late-stage prostate cancer – The U.S. Food and Drug Administration approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).

Acupuncture relieves hot flashes from prostate cancer treatment

Acupuncture relieves hot flashes from prostate cancer treatment – Acupuncture provides long-lasting relief to hot flashes, heart palpitations and anxiety due to side effects of the hormone given to counteract testosterone, the hormone that induces prostate cancer, according to a study published in the April issue of the International Journal of Radiation Oncology?Biology?Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

Antidepressant may reduce menopausal hot flashes

Use of Antidepressant Associated With Reduction in Menopausal Hot Flashes – Women who were either in the transition to menopause or postmenopausal experienced a reduction in the frequency and severity of menopausal hot flashes with the use of the antidepressant medication escitalopram, compared to women who received placebo.

49% breast cancer patients adhere to hormonal therapy regimen

Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds – A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half ? approximately 49 percent ? completed their full regimen of hormone therapy according to the prescribed schedule.

Exercise may keep cancer patients healthier

Exercise may keep cancer patients healthier during, after treatment – Breast and prostate cancer patients who regularly exercise during and after cancer treatment report having a better quality of life and being less fatigued, according to researchers at Henry Ford Hospital in Detroit.

Few US women take tamoxifen to prevent breast cancer

Few women take tamoxifen to prevent breast cancer – Researchers with the National Cancer Institute (NCI) have found that the prevalence of tamoxifen use for the prevention of breast cancer among women without a personal history of breast cancer is very low.

Low income breast cancer patients skipping hormonal therapy

Low-income breast cancer patients skipping hormonal therapy, increasing their risks – Many low-income women are failing to take the hormonal therapy prescribed as part of their breast cancer treatment, possibly lowering their survival rates, according to a study led by a researcher in the Duke Comprehensive Cancer Center.